Specialist in the development of light-activated antimicrobials Ondine Biomedical has released preliminary results of its North American Lantern pivotal Phase 3 clinical trial.
The 5,188 study evaluated its nasal photodisinfection technology for the prevention of surgical site infections (‘SSIs’) that demonstrated a 40% relative reduction in 30-day SSIs and met the trial’s pre-specified Bayesian criterion for treatment benefit.
The Lantern safety profile consistent with more than a decade of prior clinical experience with nasal photodisinfection, (also known as antimicrobial photodynamic therapy or “aPDT”); to date, more than 250,000 patient treatments were performed outside the United States in hospitals across Canada and in the UK, Mexico, Australia and the EU. No treatment-related serious safety concerns were identified in the topline review. These findings remain subject to completion of detailed efficacy, safety, subgroup and other analyses.
Surgical site infections remain one of the most serious complications of surgery, causing substantial patient morbidity, hospital readmissions, prolonged hospital stays and deaths. U.S. data have estimated that patients who develop an SSI face a two- to 11-fold increased risk of death compared with surgical patients without an infection. The CDC reports that an SSI can extend a patient’s hospital stay by approximately 9.7 days and increase hospitalisation costs by more than $20,000 each, adding over $10 billion annually to USA healthcare costs. In public healthcare systems, SSIs add to surgical wait lists as each SSI displaces 2-3 new surgeries adding to staff and budgetary burdens. The total addressable US market for surgical site and ICU infection prevention exceeds $3 billion annually.
The 5,188-patient cluster-randomized, standard-of-care-controlled superiority study involved 18 hospitals in Canada and the US. The US arm had 14 hospitals, and recruited the majority of the patients, through HCA Healthcare Research Institute. The Canadian arm of this RCT study recruited in four leading Canadian tertiary and academic medical centres each representing major referral hubs for trauma, surgical, and critical care. The Canadian sites included Foothills Medical Centre and Rockyview General Hospital in Calgary, University of Alberta Hospital in Edmonton, and Royal Columbian Hospital in New Westminster, BC.
Ondine plans to request a pre-New Drug Application (“pre-NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) to discuss the detailed Lantern results and the Company’s planned future regulatory submissions. Results will be submitted for presentation at a major scientific meeting and for publication in one or more peer-reviewed medical journals.
Carolyn Cross, Chief Executive Officer of Ondine Biomedical, commented: “The Lantern results represent an important milestone for Ondine and for our development programme in surgical site infection prevention. Surgical site infections remain a major cause of avoidable complications following surgery, while increasing antibiotic resistance and poor patient home compliance makes prevention using rapid, broad spectrum, non-antibiotic approaches increasingly important.
“We are deeply grateful to the patients, investigators, clinical research teams and healthcare professionals at HCA Healthcare Research Institute and at four Canadian hospitals, whose joint participation made this large study possible. Our prior work in Canada and other countries over more than a decade has supported the potential benefits of nasal photodisinfection for patients and healthcare providers, and we look forward to engaging with the FDA through the regulatory process to bring this technology into the United States.”